Loading clinical trials...

Similarities and Differences of Biological Therapies for Severe Asthma. | Clinical Trials | Clareo Health

UNKNOWN

Similarities and Differences of Biological Therapies for Severe Asthma.

NCT04665141•Clinica Universidad de Navarra, Universidad de Navarra

Summary

This is an ambispective multicenter longitudinal observational study to evaluate the efficacy and safety profile of biological therapies in patients diagnosed with severe asthma in real life conditions.

Detailed Description

The use of biologicals to treat severe asthma has been implemented in a regular basis while information on long term effectiveness and safety is lacking. It is necessary to establish strategies to closely monitor the possible occurrence of reactions, adverse effects of innovative biological medicines used to treat severe asthma. In this study the investigators want to evaluate the comparative effectiveness, utilization patterns, long-term safety, and use in special groups in real-life conditions in severe asthma.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals of any age: adults and children.
•Diagnosis of severe asthma as given by the treating physician, and defined as an asthma that remains uncontrolled in despite adherence with maximal optimized therapy and treatment of contributed factors, or asthma that worsens when high dose treatment is decreased.
•Being treated or not (control group) with biological drugs.
•Signed Informed Consent.

Exclusion Criteria

•None.

Locations (1)

Hospital Civil-Hospital Regional Universitario de Málaga

Málaga, Spain

Key Dates

Start Date

April 7, 2021

Primary Completion Date

November 1, 2022

Completion Date

November 1, 2022

Last Updated

April 27, 2021

Enrollment

600

ESTIMATED participants

Conditions

Asthma

Interventions

Mepolizumab

BIOLOGICAL

Omalizumab

BIOLOGICAL

Reslizumab

BIOLOGICAL

Benralizumab

BIOLOGICAL

Dupilumab

BIOLOGICAL

Contacts

Marta López de Calle

CONTACT

+34948425600 mlopezdecal@unav.es

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

RECRUITING

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897

Asthma

View study

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 27, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Similarities and Differences of Biological Therapies for Severe Asthma.

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma